The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $1.41 in the prior trading day, Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed at $1.38, down -2.13%. In other words, the price has decreased by -$2.13 from its previous closing price. On the day, 2.59 million shares were traded. MRNS stock price reached its highest trading level at $1.55 during the session, while it also had its lowest trading level at $1.37.
Ratios:
Our goal is to gain a better understanding of MRNS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.01 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 6.58 whereas as Long-Term Debt/Eq ratio is at 5.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on April 16, 2024, Downgraded its rating to Neutral and sets its target price to $2 from $20 previously.
On April 15, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $24 to $3.
Oppenheimer Downgraded its Outperform to Perform on August 11, 2023, whereas the target price for the stock was revised from $14 to $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Shafer Christina sold 2,153 shares for $9.56 per share. The transaction valued at 20,583 led to the insider holds 60,308 shares of the business.
MANNING MARTHA E sold 1,894 shares of MRNS for $18,126 on Feb 20 ’24. The SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares after completing the transaction at $9.57 per share. On Feb 16 ’24, another insider, Braunstein Scott, who serves as the CHAIRMAN AND CEO of the company, sold 11,850 shares for $9.94 each. As a result, the insider received 117,789 and left with 223,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 75804776 and an Enterprise Value of 35476760. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.43 while its Price-to-Book (P/B) ratio in mrq is 4.49. Its current Enterprise Value per Revenue stands at 1.145 whereas that against EBITDA is -0.281.
Stock Price History:
Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -83.89%, while the 200-Day Moving Average is calculated to be -83.44%.
Shares Statistics:
The stock has traded on average 1.57M shares per day over the past 3-months and 7861400 shares per day over the last 10 days, according to various share statistics. A total of 54.58M shares are outstanding, with a floating share count of 50.81M. Insiders hold about 7.01% of the company’s shares, while institutions hold 102.27% stake in the company. Shares short for MRNS as of 1711584000 were 3474895 with a Short Ratio of 2.21, compared to 1709164800 on 3427374. Therefore, it implies a Short% of Shares Outstanding of 3474895 and a Short% of Float of 6.41.
Earnings Estimates
Marinus Pharmaceuticals Inc (MRNS) is currently under the scrutiny of Moderna, Inc. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $18.33, with high estimates of $43.34 and low estimates of $1.38.
